ShareValue scores for BBTX: Valuation 50, Quality 50, Growth 50, Health 52.
BBTXNASDAQ
Bambusa Therapeutics, Inc. Common stock
$15.85
(-1.37%)
Updated
BBTXNASDAQ
Bambusa Therapeutics, Inc. Common stock
Updated
Pulse
Pulse
Fundamental Rating
Value Trap Risk
If P/E met sector median
Rating
Trap Risk
P/E to median
Company Details
Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis. It also develops BBT002, a long-acting bispecific antibody for respiratory and other Type 2 inflammatory diseases. Additionally, the company develops BBT003, a long-acting bispecific antibody for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The company also develops BBT004 for depletion of pathogenic B cells and antibody-producing plasma cells in autoantibody-driven autoimmune diseases. The company operates in the United States, Australia, New Zealand, China, Europe, and internationally. Bambusa Therapeutics, Inc. was incorporated in 2024 and is based in Boston, Massachusetts.
Score Analysis
AI Investment Thesis
Bambusa Therapeutics, Inc. Common stock screens as fairly valued versus its sector, with the $14.99 price sitting 6.3% below the $16.00 IPO price and $745.9M cap reflecting a pre-revenue pipeline rather than earnings.
The most decision-relevant fundamental is financial health: the October 29 IPO raised $168.9M gross, giving a clinical-stage, no-revenue company a cash runway that dwarfs any profitability metric peers report.
The key catalyst was the October 29 pricing of its upsized IPO at $16.00, 10.6M shares for $168.9M gross, funding BBT001's advance toward a Phase 2b trial.